Skip to main content
OpenTrials

Clinical trial condition

Infection, Human Immunodeficiency Virus

Explore clinical trials studying Infection, Human Immunodeficiency Virus. Study availability and eligibility vary by location and protocol.

107 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Infection, Human Immunodeficiency Virus trial results

Completed

Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex With Men

NCT03310515

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +17 more
Locations
  • GSK Investigational Site Guangzhou, Guangdong, China
  • GSK Investigational Site Shenyang, Liaoning, China
  • GSK Investigational Site Chengdu, Sichuan, China
  • GSK Investigational Site Hangzhou, Zhejiang, China
View Trial Details
Completed

Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults

NCT03045861

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Bakersfield, California, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Los Angeles, California, United States
View all 14 locations
View Trial Details
Completed

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

NCT01641809

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Bakersfield, California, United States
View all 48 locations
View Trial Details
Completed

Phase 4 Study of Dolutegravir (DTG) in Russian Federation

NCT03314064

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Kazan', Russia
  • GSK Investigational Site Kemerovo, Russia
  • GSK Investigational Site Krasnodar, Russia
  • GSK Investigational Site Moscow, Russia
View Trial Details

Related conditions